ArticleJournal of cellular and molecular medicine2019
Lipidomic characteristics and clinical findings of epileptic patients treated with valproic acid.
Article in Journal of cellular and molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Effects of Antiseizure Medications on Lipid Profile and Weight in Patients with Epilepsy: A Systematic Review with Meta-analysis.CNS drugs · 2025Pooled it
- Mechanisms of weight gain associated with valproic acid: a scoping review.European archives of psychiatry and clinical neuroscience · 2026Article
- The associations between epilepsy, metabolism, and their clinical implications.Frontiers in endocrinology · 2026Review
- Mechanisms Underlying the Protective Effects of Obeticholic Acid-activated FXR in Valproic Acid-induced HepatotoxicityCurrent computer-aided drug design · 2025Article
- Unveiling the influence of caffeine on topiramate: metabolomic marker analysis using liquid chromatography-mass spectrometry.Frontiers in molecular biosciences · 2025Article
- Phospholipidomics in Clinical Trials for Brain Disorders: Advancing our Understanding and Therapeutic Potentials.Molecular neurobiology · 2024Review
- Article
- Pre-treatment risk predictors of valproic acid-induced dyslipidemia in pediatric patients with epilepsy.Frontiers in pharmacology · 2024Article
- Valproate-Induced Metabolic Syndrome.Biomedicines · 2023Review
- Capsaicin combined with dietary fiber prevents high-fat diet associated aberrant lipid metabolism by improving the structure of intestinal flora.Food science & nutrition · 2023Article
- Metabolomics Provides Novel Insights into Epilepsy Diagnosis and Treatment: A Review.Neurochemical research · 2022Review
- Integrative omics analysis reveals the protective role of vitamin C on perfluorooctanoic acid-induced hepatoxicity.Journal of advanced research · 2022Article
- Valproic Acid: A Potential Therapeutic for Spinal Cord Injury.Cellular and molecular neurobiology · 2021Review
- Lipidomic characteristics and clinical findings of epileptic patients treated with valproic acid.Journal of cellular and molecular medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Our early study has found valproic acid (VPA)-induced lipid dysmetabolism in animal model, however, the details of lipid profiling of VPA-treated epileptic patients remain unknown. Therefore, in this study, the blood samples of VPA-treated epileptic patients and VPA-free controls were collected for lipidomic and biochemical assays. As results, clinical data showed the changes of some blood lipid molecules in VPA-treated epileptic patients. In lipidomic assays, all 3797 annotated positive ions were identified prior to the data validation. In addition, the number of differentially expressed lipids were identified. And the 133 lipid molecules in VPA-treated cases were significantly up-regulated when compared to those in controls, while other 250 lipid metabolites were down-regulated. Further, these lipid metabolites were mainly constituted with glycerolipids, glycerophopholipids, fatty acyls, sterol lipids. In addition, the most significant elevations of metabolite molecules of triglyceride, sphingomyelin, phosphorylcholine, ceramides, phenolic phthiocerol, as well as topped reductions of phosphoethanolamines, diradylglycerols, 1α,25-dihydroxy-24-oxo-22-oxavitamin D3, 2-deoxy-20-hydroxy-5alpha-ecdysone 3-acetate, dolichyl-4 phosphate were identified respectively. Taken together, these clinical findings demonstrate that negative impacts of exposure to VPA on expression of lipid mediators, progressively disrupting the functions of lipid molecules. Interestingly, these differentially expressed metabolites may be potential biomarkers for screening VPA-induced dyslipidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.